J&J resumes PFA cases, but analysts warn safety may hamper rollout
J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S. and globally” and lead doctors to “de-prioritize Varipulse.”
J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S. and globally” and lead doctors to “de-prioritize Varipulse.”
